Shravan Shetty, Managing Director, Primus Partners, highlighted the importance of India's $10 billion generic drug exports to the US for domestic pharma companies. He emphasized that potential tariff exemptions on generics would protect this vital revenue stream. Additionally, he said the recent market recovery reflects a rebound from previous declines, with further growth likely as generics gain traction in the US due to widening price gaps with branded drugs.